Shire
upgrades Baxalta cost savings after Q2
earnings beat
LONDON, Aug 2 (Reuters) - Drugmaker
Shire upgraded its guidance for 2016 on Tuesday,
after it hiked the predicted
cost saving target for its $32 billion acquisition of rare disease ***** specialist...
